CHICAGO – Greg Perius has joined AltaThera Pharmaceuticals as the Director of Operations & Corporate Development.
At Altathera, Perius will support key strategic initiatives related to business development and licensing. He will also play a role in Sotalol IV marketing to support the brand's current growth.
Perius has 25 years of experience in the pharmaceutical industry. He has worked with both fortune 100 and early-growth organizations, and has experience in sales, sales training, and marketing. Most recently, Perius was the General Manager, U.S. Commercial for a small start-up, Vansen Pharma where he grew the company to 35 employees and $8 million in annual revenue.
Perius expects to produce similar results for AltaThera based on his 16 years of cardiovascular expertise. With BMS, he led the commercial development of a single bolus thrombolytic in phase 2. His antiarrhythmic experience includes Rythmol® (propafenone), where he was lead Product Manager for the brand at Knoll Pharmaceuticals.
About AltaThera: AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on critical care and alternative therapeutics for the unmet medical needs of patients with severe, and often rare, disorders for which few effective treatments are available.